Major Depressive Disorder Clinical Trial
— TMSADOfficial title:
Transcranial Magnetic Stimulation for Adolescent Depression
NCT number | NCT01731678 |
Other study ID # | E-24656 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | November 2012 |
Est. completion date | December 2018 |
Verified date | September 2020 |
Source | University of Calgary |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Major depression (or MDD) in adolescents is a major public health problem. MDD affects
approximately 15% of adolescents; it is associated with impairment in social, family, and
academic functioning, and it is a major risk factor for suicide - a leading cause of death in
adolescents . Unfortunately, there is a paucity of treatment options for this age group.
Selective serotonin reuptake inhibitors (SSRIs) are the only class of medications approved
for treating MDD in adolescents, but rates of remission following treatment with SSRIs are
only 30 to 45 percent. Cognitive behavior therapy is associated with similar remission rates
and access is limited. Most adolescents will require more than one therapeutic intervention
in order to achieve full symptom control. Collectively, there is overwhelming evidence that
additional treatment options are urgently needed to improve outcomes for teens with MDD. One
novel treatment for adolescent MDD is repetitive transcranial magnetic stimulation (rTMS).
Studies in children have been limited (a total of 23 cases). This is surprising given the
evidence suggesting younger adult subjects with MDD respond better to rTMS (56% response
rate) than older subjects. This limited experience with rTMS for adolescent MDD represents a
substantial gap in the knowledge, recently recognized in publications calling for further
study of rTMS in adolescent depression. Most importantly, the mechanism of action of rTMS in
adolescent MDD is not well understood. The objective of this application is to develop an
understanding of the brain alterations associated with the positive clinical changes that
occur with rTMS in adolescent MDD. Such knowledge will provide the basis for pursuing rTMS
for adolescent MDD as a rational therapeutic technique.
Specific Aim: To compare the effect of rTMS on DLPFC glutamate concentration in adolescent
MDD. The investigators hypothesize an increase (normalization to controls) in DLPFC glutamate
after three weeks of rTMS. Furthermore, the change in glutamate concentration will correlate
with a change in MDD symptoms.
Status | Completed |
Enrollment | 39 |
Est. completion date | December 2018 |
Est. primary completion date | April 2018 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 12 Years to 21 Years |
Eligibility |
Inclusion Criteria: - age (12-22 years), - MDD failing to respond to at least one SSRI trial (minimum 8 weeks treatment at an adequate dose; determined retrospectively), and - informed consent. Healthy controls with no psychiatric history (who do not receive rTMS) will undergo MRI scans to allow for comparison with MDD patients. Exclusion Criteria: - previous seizures or epilepsy, - hypertension, - additional neurological or psychiatric diagnoses (specifically: bipolar disorder, psychosis, pervasive developmental disorder, eating disorders, and post-traumatic stress disorder). As 3T MRI will be used, pregnancy is exclusionary. |
Country | Name | City | State |
---|---|---|---|
Canada | Alberta Children's Hospital | Calgary | Alberta |
Lead Sponsor | Collaborator |
---|---|
University of Calgary |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Interim Analysis - rTMS Tolerability Scale | There will be an interim analysis to review safety, tolerability (as measured by our rTMS tolerability scale) after the first 10 rTMS patients. Should there be significant concerns, the team will terminate the study. Ten was selected as it is close to previous reports and should be informative. | After the first 10 patients are completed | |
Other | Interim Analysis - Ham-D | There will be an interim analysis to review response (Ham-D) after the first 10 rTMS patients. Should there be significant concerns, the team will terminate the study. Ten was selected as it is close to previous reports and should be informative. | After the first 10 patients are completed | |
Primary | Hamilton Depression Rating Scale | Response defined as: a reduction of Hamilton Depression Rating Scale score of 50% or more Name: Hamilton Depression Rating Scale Construct: Depression Range: 0-52 Direction: Higher is worse depression symptoms/severity Sub-scales: Not applicable. Reference: Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol. 1967 Dec;6(4):278-96. | Three weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05537558 -
Precision Medicine for the Prediction of Treatment (PROMPT) Response (PROMPT)
|
||
Terminated |
NCT02192099 -
Open Label Extension for GLYX13-C-202, NCT01684163
|
Phase 2 | |
Completed |
NCT03142919 -
Lipopolysaccharide (LPS) Challenge in Depression
|
Phase 2 | |
Recruiting |
NCT05547035 -
Identification of Physiological Data by a Wearable Monitor in Subjects Suffering From Major Depression Disorders
|
N/A | |
Terminated |
NCT02940769 -
Neurobiological Effects of Light on MDD
|
N/A | |
Recruiting |
NCT05892744 -
Establishing Multimodal Brain Biomarkers for Treatment Selection in Depression
|
Phase 4 | |
Recruiting |
NCT05537584 -
SMART Trial to Predict Anhedonia Response to Antidepressant Treatment
|
Phase 4 | |
Active, not recruiting |
NCT05061706 -
Multicenter Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
|
Phase 3 | |
Completed |
NCT04479852 -
A Study of the Safety and Efficacy of SP-624 in the Treatment of Adults With Major Depressive Disorder
|
Phase 2 | |
Recruiting |
NCT04032301 -
Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans
|
Phase 1 | |
Recruiting |
NCT05527951 -
Enhanced Measurement-Based Care Effectiveness for Depression (EMBED) Study
|
N/A | |
Completed |
NCT03511599 -
Cycloserine rTMS Plasticity Augmentation in Depression
|
Phase 1 | |
Recruiting |
NCT04392947 -
Treatment of Major Depressive Disorder With Bilateral Theta Burst Stimulation
|
N/A | |
Recruiting |
NCT05895747 -
5-HTP and Creatine for Depression R33 Phase
|
Phase 2 | |
Recruiting |
NCT05273996 -
Predictors of Cognitive Outcomes in Geriatric Depression
|
Phase 4 | |
Recruiting |
NCT05813093 -
Interleaved TMS-fMRI in Ultra-treatment Resistant Depression
|
N/A | |
Recruiting |
NCT05135897 -
The Neurobiological Fundaments of Depression and Its Relief Through Neurostimulation Treatments
|
||
Enrolling by invitation |
NCT04509102 -
Psychostimulant Augmentation of Repetitive TMS for the Treatment of Major Depressive Disorder
|
Early Phase 1 | |
Recruiting |
NCT06026917 -
Assessing Dopamine Transporter Occupancy in the Patients With Depression Brain With Toludesvenlafaxine Hydrochloride Extended-Release Tablets Using 11C-CFT Positron Emission Tomography (PET)
|
Phase 4 | |
Recruiting |
NCT06145594 -
EMA-Guided Maintenance TMS for Depression
|
N/A |